睿知中国医院研究地图
候选清单

正在招募乳腺癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由蚌埠医学院第一附属医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方蚌埠医学院第一附属医院First Affiliated Hospital of Bengbu Medical University蚌埠医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT05192798,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 80 岁;性别:仅女性

    登记记录的入选字段

  2. For subjects who have previously undergone adjuvant/neoadjuvant therapy, the time from the end of the last chemotherapy (including taxanes) to randomization should be ≥12 months; The time from the end of radical radiotherapy to randomization should be ≥6 months.

    入选标准第 7 条

  3. Eastern Cooperative Oncology Group performance status (ECOG PS) : 0-2;

    入选标准第 5 条

  4. Absolute neutrophil count ≥ 1.5 x 10\^9 / L;

    入选标准第 9 条

    Platelet count ≥ 100 x 10\^9 / L;

    入选标准第 10 条

    Hemoglobin ≥ 90 g/L;

    入选标准第 11 条

    Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤2.5 × upper limit of normal (ULN); ALT and AST≤5 × ULN if liver metastasis is present;

    入选标准第 12 条

    Creatinine clearance rate(Ccr) ≥60 mL/min according to the Cockcroft-Gault formula;

    入选标准第 13 条

    Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 × ULN, and international normalized ratio (INR)≤1.5 × ULN.

    入选标准第 14 条

  5. Presence of at least one measurable lesion according to RECIST 1.1;

    入选标准第 3 条

  6. Previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix;

    排除标准第 11 条

  7. Patients who are pregnant or breast-feeding;

    排除标准第 1 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义)。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT05192798,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Female patients aged ≥18 years and ≤80 years;
  2. Patients with recurrent or metastatic triple negative breast cancer confirmed by histopathology and imaging;
  3. Presence of at least one measurable lesion according to RECIST 1.1;
  4. Expected survival ≥3 months;
  5. Eastern Cooperative Oncology Group performance status (ECOG PS) : 0-2;
  6. Patients who have not previously received antitumor systemic therapy for the stage of relapse or metastasis;
  7. For subjects who have previously undergone adjuvant/neoadjuvant therapy, the time from the end of the last chemotherapy (including taxanes) to randomization should be ≥12 months; The time from the end of radical radiotherapy to randomization should be ≥6 months.
  8. Major organs show good function, and the relevant examination indexes within 7 days prior to randomization meet the following requirements:
  9. Absolute neutrophil count ≥ 1.5 x 10\^9 / L;
  10. Platelet count ≥ 100 x 10\^9 / L;
  11. Hemoglobin ≥ 90 g/L;
  12. Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤2.5 × upper limit of normal (ULN); ALT and AST≤5 × ULN if liver metastasis is present;
  13. Creatinine clearance rate(Ccr) ≥60 mL/min according to the Cockcroft-Gault formula;
  14. Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5 × ULN, and international normalized ratio (INR)≤1.5 × ULN.
  15. Subjects voluntarily agree to participate in the study and sign informed consent, with good compliance and being accessible for treatment and follow-up.

排除标准:Exclusion Criteria:

  1. Patients who are pregnant or breast-feeding;
  2. Patients with multiple factors affecting oral medication (such as swallow inability, chronic diarrhea and intestinal obstruction);
  3. Known hypersensitivity reaction to any of the components of the treatment;
  4. Peripheral neuropathy ≥ grade 2, whatever the cause;
  5. Serious other diseases as infections (hepatitis B, C and HIV), recent myocardial infarction, clinical signs of cardiac failure or clinically significant arrhythmias or on screening, any of the following cardiac parameters: bradycardia (heart rate <50 at rest) or heart rate-corrected QT interval via Fridericia (QTcF) ≥470 msec.
  6. Patients with urinary protein ≥++ indicated by routine urine examination, and the 24-hour urine protein level was confirmed to be > 1.0g;
  7. Patients with imaging showing that the tumor has invaded important blood vessels or the investigator judges that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during the follow-up study;
  8. Patients who have experienced arteriovenous or venous thrombosis events within 6 months prior to randomization, such as cerebrovascular accident (including temporary ischemic attack), deep vein thrombosis and pulmonary embolism;
  9. Any bleeding or bleeding event ≥grade 3 within 4 weeks prior to the first dose of therapy; Or the presence of unhealed wounds, fractures, gastrointestinal diseases such as gastric and duodenal active ulcers, ulcerative colitis, or active bleeding of unresected tumors, or other conditions that may cause gastrointestinal bleeding or perforation as determined by the investigator;
  10. Uncontrolled effusion management (pleural effusion, pericardial effusion, or ascites) which requires frequent drainage procedures;
  11. Previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix;
  12. Participants in clinical trials of other antitumor drugs within 4 weeks prior to randomization;
  13. Other circumstances in which participation in the study would be inappropriate as determined by the investigator.

引自 ClinicalTrials.gov, NCT05192798, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT05192798,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT05192798